Animal models of amyloid-beta-related pathologies in Alzheimer's disease.
In the early 1990s, breakthrough discoveries on the genetics of Alzheimer's disease led to the identification of missense mutations in the amyloid-beta precursor protein gene. Research findings quickly followed, giving insights into molecular pathogenesis and possibilities for the development of new types of animal models. The complete toolbox of transgenic techniques, including pronuclear oocyte injection and homologous recombination, has been applied in the Alzheimer's disease field, to produce overexpressors, knockouts, knockins and regulatable transgenics. Transgenic models have dramatically advanced our understanding of pathogenic mechanisms and allowed therapeutic approaches to be tested. Following a brief introduction to Alzheimer's disease, various nontransgenic and transgenic animal models are described in terms of their values and limitations with respect to pathogenic, therapeutic and functional understandings of the human disease.
Philipson
Ola
O
Department of Public Health and Caring Sciences/Molecular Geriatrics, Uppsala University, Sweden.
Lord
Anna
A
Gumucio
Astrid
A
O'Callaghan
Paul
P
Lannfelt
Lars
L
Nilsson
Lars N G
LN
D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology* / Q000503:physiopathology; D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000235:genetics; D000818:Animals; D030801:Animals, Genetically Modified; D004195:Disease Models, Animal; D006801:Humans; D008969:Molecular Sequence Data; D020125:Mutation, Missense
D016229:Amyloid beta-Peptides